MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2

Cancer Research

Volumn 71, Issue 2, 2011, Pages 583-592

  Ma, Stephanie ^a,f   Chan, Yuen Piu ^a   Kwan, Pak Shing ^a   Lee, Terence K ^a   Yan, Mingxia ^b   Tang, Kwan Ho ^a   Ling, Ming Tat ^c   Vielkind, Juergen R ^d,e   Guan, Xin Yuan ^a   Chan, Kwok Wah ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^d BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; LENTIVIRUS VECTOR; MESSENGER RNA; MICRORNA; MICRORNA 616; PLACENTA PROTEIN 5; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; BIOINFORMATICS; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CASTRATION; CELL PROLIFERATION; CELL STRAIN LNCAP; CONTROLLED STUDY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORCHIECTOMY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN MICROARRAY;

ANDROGENS; ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; GLYCOPROTEINS; HUMANS; MALE; MICE; MICE, NUDE; MICRORNAS; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 78751527881     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2587     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
3. He L, Hannon GJ. microRNAs: small RNAs with a big role in gene regulation. Nat Rev Genetics 2004;5:522-32.
4. Calin GA, Croce CM. microRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.
5. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.
6. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8.
7. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T, et al. MicroRNA expression profiling in prostate cancer. Cancer Res 2007;67:6130-5.
8. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008;68:6162-70.
9. Ozen M, Creighton CJ, Ozdemir M, Ittmann M. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2007;27:1788-93.
10. Galardi S, Mercatelli N, Giorda E, Massalini S, Frajese GV, Ciafre SA, et al. miR-221 and miR- expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem 2007;282:23716-24.
11. ChenX,Gong J,ZengH,Chen N,HuangR,Huang Y, et al.MicroRNA145 targetsBNIP3 and suppresses prostate cancer progression.Cancer Res 2010;70:2728-38.
12. Lin SL, Chiang A, Chang D, Ying SY. Loss of miR-146a function in hormone-refractory prostate cancer. RNA 2008;14:7-24.
13. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, et al. miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Res 2009;69:7165-9.
14. Sun T, Wang Q, Balk S, Brown M, Lee GS, Kantoff P, et al. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 2009;69:3356-63.
15. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, et al. An androgenregulated miRNA suppresses Bak1 expression and induces androgen- independent growth of prostate cancer cells. Proc Natl Acad Sci U S A 2007;104:19983-8.
16. Webber MM, Bello D, Quader S. Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. II. Tumorigenic cell lines. Prostate 1997;30:58-64.
17. Choo CK, Ling MT, Chan KW, Tsao SW, Zheng Z, Zhang D, et al. Immortalization of human prostate epithelial cells by HPV 16 E6/E7 open reading frames. Prostate 1999;40:150-8.
18. Bright RK, Vocke CD, Emmert-Buck MR, Duray PH, Solomon D, Fetsch P, et al. Generation and genetic characterization of immortal human prostate epithelial cell lines derived from primary cancer specimens. Cancer Res 1997;57:995-1002.
19. van Steenbrugge GJ, van Uffelen CJ, Bolt J, Schroder FH. The human prostatic cancer cell line LNCaP and its derived sublines: an in vitro model for the study of androgen sensitivity. J Steroid Biochem Molec Biol 1991;40:207-14.
20. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
21. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, et al. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 2004;60:257-71.
22. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-73.
23. Sprecher CA, Kisiel W, Mathewes S, Foster DC. Molecular cloning, expression, and partial characterization of a second human tissue- factor-pathway inhibitor. Proc Natl Acad Sci U S A 1994; 91:3353-7.
24. Sierko E, Wojtukiewicz MZ, Kisiel W. The role of tissue factor pathway inhibitor-2 in cancer biology. Semin Thromb Hemost 2007;33:653-9.
25. Wong CM, Ng YL, Lee JM, Wong CC, Cheung OF, Chan CY, et al. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. Hepatology 2007; 45:1129-38.
26. Yang Z, Pan J. A novel role for tissue factor pathway inhibitor-2 (TFPI- 2) in the therapy of human esophageal carcinoma. Hum Gene Ther 2008;20:41-9.
27. Nobeyama Y, Okochi-Takada E, Furuta J, Miyagi Y, Kikuchi K, Yamamoto A, et al. Silencing of tissue factor pathway inhibitor-2 gene in malignant melanomas. Int J Cancer 2007;121:301-7.
28. Rao CN, Lakka SS, Kin Y, Konduri SD, Fuller GN, Mohanam S, et al. Expression of tissue factor pathway inhibitor 2 inversely correlates during the progression of human gliomas. Clin Cancer Res 2001; 7:570-6.
29. Tasiou A, Konduri SD, Yanamandra N, Dinh DH, Olivero WC, Gujrati M, et al. A novel role of tissue factor pathway inhibitor-2 in apoptosis of malignant human gliomas. Int J Oncol 2001;83:325-33.
30. Sato N, Parker AR, Fukushima N, Miyagi Y, Iacobuzio-Donahue CA, Eshleman JR, et al. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene 2005; 24:850-8.
31. Rollin J, Iochmann S, Blechet C, Hube F, Regina S, Guyetant S, et al. Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer. Br J Cancer 2005; 92:775-83.
32. Konduri SD, Tasiou A, Chandrasekar N, Rao JS. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2) decreases the invasiveness of prostate cancer cells in vitro. Int J Oncol 2001; 18:127-31.